Indivior's (INDV) Overweight Rating Reiterated at Piper Sandler

Indivior (NASDAQ:INDV - Get Free Report)'s stock had its "overweight" rating restated by stock analysts at Piper Sandler in a research note issued on Friday, Benzinga reports. They currently have a $16.00 target price on the stock, up from their prior target price of $15.00. Piper Sandler's target price indicates a potential upside of 77.78% from the stock's previous close.

Separately, Craig Hallum reduced their price objective on shares of Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, October 11th.

Indivior Stock Performance

Shares of INDV traded up $0.23 during trading hours on Friday, hitting $9.00. The company's stock had a trading volume of 449,985 shares, compared to its average volume of 446,239. The company has a market cap of $1.24 billion, a price-to-earnings ratio of 901.00 and a beta of 0.68. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The business has a 50 day simple moving average of $10.20 and a two-hundred day simple moving average of $13.90. Indivior has a 52-week low of $7.33 and a 52-week high of $23.22.

Indivior (NASDAQ:INDV - Get Free Report) last posted its earnings results on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.04. The firm had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. On average, equities analysts expect that Indivior will post 1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Indivior

Several hedge funds have recently bought and sold shares of INDV. Bank of New York Mellon Corp bought a new stake in Indivior during the second quarter valued at approximately $188,000. VELA Investment Management LLC bought a new stake in Indivior during the second quarter valued at approximately $235,000. XTX Topco Ltd bought a new stake in Indivior during the second quarter valued at approximately $249,000. Cubist Systematic Strategies LLC lifted its position in Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company's stock valued at $407,000 after purchasing an additional 6,121 shares during the last quarter. Finally, Forsta AP Fonden bought a new stake in Indivior during the first quarter valued at approximately $641,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.